Global Sales of ADHD Drugs Are Forecast to Reach US$4.3 Billion By 2012 - Market Research Available on CNS Drug Discoveries 2006: Attention Deficit Hyperactivity Disorder
Posted on: Friday, 15 December 2006, 09:01 CST
Research and Markets (http://www.researchandmarkets.com/reports/c47133) has announced the addition of Espicom Business Intelligence's CNS Drug Discoveries: Attention Deficit Hyperactivity Disorder Chapter to their offering.
ADHD is now the 9th largest segment of the CNS market by sales with growth of 8% year-on-year. Find out more in this chapter of CNS Drug Discoveries.
The value of the ADHD market was US$2.6 billion in 2005 and it is now the 9th largest segment of the CNS market by sales with growth of 8% year-on-year. Global sales of ADHD drugs are forecast to reach US$4.3 billion by 2012. This will be due to greater penetration in the treatment of new patients, particularly adult ADHD, improvements in patient compliance due to the launch of new formulations, new non-schedule II drugs and the development of novel classes of drugs in late-stage clinical trials.
There has been a significant increase in ADHD diagnosis and prescription of medicine since the early 1990s due to wider understanding of the condition in the mental health community, increased use of medication and healthcare coverage and the launch of ADHD-specific drugs (from 2000 onwards). ADHD is one of the most common psychiatric disorders of childhood and approximately 50% to 70% of children with ADHD will continue to experience symptoms into adulthood. In 2000, it was estimated that 4-5 million individuals (mainly children) were diagnosed with ADHD of whom 75-85% were treated with psychostimulants. Over 8 million adults in the US may exhibit the symptoms of ADHD, while only an estimated 600,000 are being treated.
Global ADHD market
Approximately 90% of ADHD global sales were derived from the US in 2005, with the remainder from Europe. This is largely due to a higher diagnosis rate in pediatrics and availability of drugs for medical reimbursement. Growth in adult ADHD medications has increased exponentially whilst their use in children has slowed due to safety concerns. Growth has also been driven by the launch of new non-stimulant drugs, new patients and the development of new formulations providing flexibility in dosing and higher patient compliance. This has helped to offset the impact of generics which are beginning to emerge on the market.
Key questions answered in this chapter include:
By what size has the patient population increased in the last 10 years?
What impact is the treatment of adult ADHD treatment having on the market?
What strategy is Shire adopting to protect its ADHD franchise from generics?
What impact has Lilly's Strattera had on the market?
What market share has Novartis achieved and how?
What other companies are entering the ADHD market and how do their products stack up against the competition?
The full report covers 6 key CNS therapy areas; the information provided here is specific to just one chapter. For information on the full report please search our Website. This chapter is available for purchase separately.
Content Outline:
ATTENTION DEFICIT HYPERACTIVITY DISORDER
EXECUTIVE SUMMARY
THE FACTS
PATIENT STATISTICS
PATIENT MODEL
DRUG GROWTH DRIVERS
DRUG GROWTH RISKS/DAMPENERS
GLOBAL ADHD MARKET
GLOBAL SALES SPLIT
CURRENT TREATMENTS
ANALYSIS OF LEADING BRANDS
STIMULANTS
NON STIMULANT
GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 -- 2012
NEW DRUGS IN R&D
ANALYSIS OF PHASE III DRUGS
GLOBAL SALES FORECASTS OF PHASE III ADHD DRUGS 2006 -- 2012
ANALYSIS OF PHASE II DRUGS
GLOBAL SALES FORECASTS OF PHASE II ADHD DRUGS 2006 -- 2012 .
COMPETITOR RATIO ANALYSIS
COMPETITOR RATIO ANALYSIS - COMPANIES
DISCONTINUATION OF DRUGS
ADHD APPENDIX 1
ADHD APPENDIX 2
ADHD APPENDIX 3
ADHD APPENDIX 4
ADHD APPENDIX 5
ADHD GLOSSARY
ADHD REFERENCES
ACRONYMS
For more information visit http://www.researchandmarkets.com/reports/c47133
Source: Business Wire
Related Articles
- Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
- Amgen's Denosumab and Eli Lilly's Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
- Sales of Antiretroviral Agents Will Drive Substantial Six Percent Annual Growth in the HIV Drug Market Through 2013
- Generic Erosion Will Constrain Prostate Cancer Drug Market, Resulting in Annual Growth of Less Than 2 Percent Through 2012
- Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
- The Market for Antidepressive Drugs Is the Largest Segment of the CNS Sector With Global Sales of US$16.2 Billion in 2005 - 2006 Market Research CNS Drug Discoveries: Depression
- Bivio Networks Appoints Vice President of Worldwide Sales and Customer Support; James F. Brear Brings Extensive Experience in Driving Global Sales Growth
- The Global Drug Market for Dermatological Conditions Associated With Ageing and Lifestyle Was Estimated at US$1.8 Billion in 2005
- The Global Drug Market for Dermatological Conditions Associated With Ageing and Lifestyle is Estimated at US$1.8 Billion in 2005
 |
 |
User Comments (0)
RSS Feeds